The impact of Medicare Part D on medication treatment of hypertension

Health Serv Res. 2011 Feb;46(1 Pt 1):185-98. doi: 10.1111/j.1475-6773.2010.01183.x. Epub 2010 Sep 28.

Abstract

Objective: To evaluate Medicare Part D's impact on use of antihypertensive medications among seniors with hypertension.

Data sources: Medicare-Advantage plan pharmacy data from January 1, 2004 to December 12, 2007 from three groups who before enrolling in Part D had no or limited drug benefits, and a comparison group with stable employer-based coverage.

Study design: Pre-post intervention with a comparison group design was used to study likelihood of use, daily counts, and substitutions between angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers (ARBs).

Principal findings: Antihypertensive use increased most among those without prior drug coverage: likelihood of use increased (odds ratio = 1.40, 95 percent confidence interval [CI] 1.25-1.56), and daily counts increased 0.29 (95 percent CI 0.24-0.33). Proportion using ARBs increased from 40 to 46 percent.

Conclusions: Part D was associated with increased antihypertensive use and use of ARBs over less expensive alternatives.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiotensin II Type 1 Receptor Blockers / economics
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Angiotensin-Converting Enzyme Inhibitors / economics
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Antihypertensive Agents / economics
  • Antihypertensive Agents / therapeutic use*
  • Drug Utilization
  • Female
  • Health Services / statistics & numerical data
  • Humans
  • Hypertension / drug therapy*
  • Male
  • Medicare Part D / statistics & numerical data*
  • Socioeconomic Factors
  • United States

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents